[7] Renal function was assessed in every clinic visit, on days 1, 4, 8, and 11 of a 21-day cycle, or more frequently if indicated. Response of myeloma to treatment was defined as ≥ 50% decrease ...

Our additional preliminary studies demonstrate that dual targeting of multiple myeloma cells and BM-CAFs by CAR-T cells is ...

Multiple myeloma is a type of cancer where plasma cells ... The accumulation of M protein in the blood can result in kidney damage and kidney failure. Hypercalcemia can also impair kidney function.

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...

Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

Multiple Myeloma is a type of blood cancer that develops in plasma ... weakening the immune system and causing complications ...

4, 2024 — A new study shows strong alignment between real-world outcomes and those seen in clinical trials among a broad population of patients with relapsed or refractory multiple myeloma.

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

Multiple myeloma is a complex disease ... increased risk of infections as the immune system weakens, kidney issues and ...

Purpose: Renal impairment is a frequent complication of multiple myeloma (MM) and is associated with significant morbidity and increased early death rate. Bortezomib is active and well tolerated ...